RecruitingPHASE2, PHASE3NCT06563245

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Studying Hodgkin lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Children's Cancer Group, China
Principal Investigator
YI JIN GAO, MD
Shanghai Children's Medical Center
Intervention
Brentuximab Vedotin for Injection(drug)
Enrollment
96 enrolled
Eligibility
2-35 years · All sexes
Timeline
2024 – 2039

Study locations (1)

Collaborators

Shanghai Children's Medical Center · Najing Children's Hospital · West China Second University Hospital · Qilu Hospital of Shandong University · Tianjin Medical University Cancer Institute and Hospital · Tongji Hospital · Xiangya Hospital of Central South University · The First Affiliated Hospital of Zhengzhou University · Second Affiliated Hospital of Anhui Medical University · Children's Hospital of Hebei Province · Children's Hospital of Henan Province · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06563245 on ClinicalTrials.gov

Other trials for Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Hodgkin lymphoma →

← Back to all trials